Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming ... novel approach to selectively redirect and harness potent anti-viral memory T cells against targeted ...

This enables it to selectively deplete B cells and dampen autoimmune and inflammatory processes ... to selectively redirect and harness potent anti-viral memory T cells against targeted ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

A new study has revealed that a special group of cells in the intestines tamp down the immune responses caused by exposure to food proteins. Called 'tolerogenic dendritic cells,' these cells enable ...

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline ... novel approach to selectively redirect and harness potent anti-viral memory T cells against targeted ...

New research zeroes in on a unique group of immune cells that could transform how we treat—and possibly prevent—severe food ...

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy ...

Meloxicam is an enolcarboxamide with preferential COX-2 activity. Studies conducted on experimental models and human tissues indicate that meloxicam is a more potent inhibitor of COX-2 than COX-1 ...

Inside cells, two important enzymes act like small central regulatory hubs: dipeptidyl peptidase 8 and 9—DPP8/9 for short. Among other things, they regulate inflammatory reactions and influence ...

Altered gut microbiota is associated with resistance to chemo drugs or immune checkpoint inhibitors (ICIs), whereas ... build upon this work non-commercially, and license their derivative works on ...

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, United States ...